| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Zika Virus RNA, Qualitative TMA, Serum
Test CodeZKAVQL
CPT Codes
87662
Preferred Specimen
3 mL serum
Minimum Volume
1.5 mL
Instructions
Collect blood in a serum separator tube or a standard red-top. Allow blood to clot at room temperature. The specimen should be centrifuged as soon as possible, and serum transferred to an plastic tube.
Transport Container
Transport tube
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: Unacceptable
Refrigerated: 7 days
Frozen: 30 days
Refrigerated: 7 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Samples received in original collection container.
Methodology
Transcription Mediated Amplification
FDA Status
The test is only for use under the Food and Drug Administration's Emergency Use Authorization.
Setup Schedule
Set up: Mon-Sat; Report available: 2-3 days
Reference Range
Not detected
Clinical Significance
This test is intended for the qualitative detection of Zika virus in serum from individuals who meet the Centers for Disease Control and Prevention (CDC) clinical and epidemiological criteria for Zika virus testing. Zika viruses are primarily transmitted by Aedes aegypti and Aedes albopictus mosquitos [1].
Most individuals with Zika infections are asymptomatic. Individuals with symptomatic infections may experience fever, rash, and muscle/joint pain [2].
Per the 2019 CDC guidelines, testing is recommended only for symptomatic pregnant women with a history of living in or traveling to a geographic area at risk for Zika. For current testing guidelines, see https://www.cdc.gov/zika/hc-providers/testing-guidance.html
For individuals meeting the CDC criteria, concurrent testing of serum and urine is recommended as soon as possible after symptom onset.
Zika infection shares clinical and epidemiological features with other arbovirus infections such as Dengue and Chikungunya. For CDC guidelines on testing concurrently for Zika and Dengue, see https://www.cdc.gov/dengue/healthcare-providers/testing/testing-guidance.html
1. Subcommittee on Laboratory Practices, ASM, and Public Relations Committee, Pan American Society for Clinical Virology (PASCV). Zika virus: An Update on the Disease and Guidance for Laboratory Testing. September 2022. Accessed May 9, 2023. https://asm.org/Guideline/Zika-virus-An-update-on-the-disease-and-guidance-f
2. Sharp TM, et al. MMWR Recomm Rep. 2019 Jun 14;68(1):1-10.
Most individuals with Zika infections are asymptomatic. Individuals with symptomatic infections may experience fever, rash, and muscle/joint pain [2].
Per the 2019 CDC guidelines, testing is recommended only for symptomatic pregnant women with a history of living in or traveling to a geographic area at risk for Zika. For current testing guidelines, see https://www.cdc.gov/zika/hc-providers/testing-guidance.html
For individuals meeting the CDC criteria, concurrent testing of serum and urine is recommended as soon as possible after symptom onset.
Zika infection shares clinical and epidemiological features with other arbovirus infections such as Dengue and Chikungunya. For CDC guidelines on testing concurrently for Zika and Dengue, see https://www.cdc.gov/dengue/healthcare-providers/testing/testing-guidance.html
1. Subcommittee on Laboratory Practices, ASM, and Public Relations Committee, Pan American Society for Clinical Virology (PASCV). Zika virus: An Update on the Disease and Guidance for Laboratory Testing. September 2022. Accessed May 9, 2023. https://asm.org/Guideline/Zika-virus-An-update-on-the-disease-and-guidance-f
2. Sharp TM, et al. MMWR Recomm Rep. 2019 Jun 14;68(1):1-10.
Performing Laboratory
| Quest Diagnostics Nichols Institute |
| 33608 Ortega Highway |
| San Juan Capistrano, CA 92675-2042 |
